CA2104649A1 - Molecules antisens complementaires de sequences genomiques de vhc - Google Patents
Molecules antisens complementaires de sequences genomiques de vhcInfo
- Publication number
- CA2104649A1 CA2104649A1 CA 2104649 CA2104649A CA2104649A1 CA 2104649 A1 CA2104649 A1 CA 2104649A1 CA 2104649 CA2104649 CA 2104649 CA 2104649 A CA2104649 A CA 2104649A CA 2104649 A1 CA2104649 A1 CA 2104649A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- sequence type
- seq
- sense
- base pairs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24879692 | 1992-08-25 | ||
| JP248796/1992 | 1992-08-25 | ||
| JP42736/1993 | 1993-03-03 | ||
| JP4273693 | 1993-03-03 | ||
| JP217095/1993 | 1993-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2104649A1 true CA2104649A1 (fr) | 1994-02-26 |
Family
ID=26382474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2104649 Abandoned CA2104649A1 (fr) | 1992-08-25 | 1993-08-23 | Molecules antisens complementaires de sequences genomiques de vhc |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2104649A1 (fr) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0759979A4 (fr) * | 1994-05-10 | 1999-10-20 | Gen Hospital Corp | Inhibition par oligonucleotides antisens du virus de l'hepatite c |
| US6174868B1 (en) | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| US6391542B1 (en) | 1992-09-10 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
| US6423489B1 (en) | 1992-09-10 | 2002-07-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
| EP1002878A3 (fr) * | 1998-11-19 | 2003-11-12 | Tosoh Corporation | Oligo ADN se fixant sur ARN du virus de l'hépatite C et méthode de production |
| US6995146B2 (en) | 1992-09-10 | 2006-02-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| WO2007084567A3 (fr) * | 2006-01-17 | 2007-12-13 | Us Gov Health & Human Serv | Detection et discrimination de virus d’hepatite c, virus de l’immunodeficience humaine de type-1 et virus d’hepatite b |
| EP2071030A3 (fr) * | 2003-01-24 | 2009-07-22 | Tokyo Metropolitan Organization for Medical Research | Oligoribonucléotide ou acide nucléique de peptide qui inhibe l'action du virus de l'hépatite C |
| US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| US8613936B2 (en) | 2009-03-13 | 2013-12-24 | Bavarian Nordic A/S | Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements |
-
1993
- 1993-08-23 CA CA 2104649 patent/CA2104649A1/fr not_active Abandoned
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6995146B2 (en) | 1992-09-10 | 2006-02-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| US6174868B1 (en) | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| US6391542B1 (en) | 1992-09-10 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
| US6423489B1 (en) | 1992-09-10 | 2002-07-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
| US6001990A (en) * | 1994-05-10 | 1999-12-14 | The General Hospital Corporation | Antisense inhibition of hepatitis C virus |
| EP0759979A4 (fr) * | 1994-05-10 | 1999-10-20 | Gen Hospital Corp | Inhibition par oligonucleotides antisens du virus de l'hepatite c |
| US6608191B1 (en) | 1995-05-30 | 2003-08-19 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| EP1002878A3 (fr) * | 1998-11-19 | 2003-11-12 | Tosoh Corporation | Oligo ADN se fixant sur ARN du virus de l'hépatite C et méthode de production |
| EP2071030A3 (fr) * | 2003-01-24 | 2009-07-22 | Tokyo Metropolitan Organization for Medical Research | Oligoribonucléotide ou acide nucléique de peptide qui inhibe l'action du virus de l'hépatite C |
| WO2007084567A3 (fr) * | 2006-01-17 | 2007-12-13 | Us Gov Health & Human Serv | Detection et discrimination de virus d’hepatite c, virus de l’immunodeficience humaine de type-1 et virus d’hepatite b |
| US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| US8613936B2 (en) | 2009-03-13 | 2013-12-24 | Bavarian Nordic A/S | Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements |
| US9163237B2 (en) | 2009-03-13 | 2015-10-20 | Bavarian Nordic A/S | Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TAN et al. | Recombinant Dengue Type 1 Virus NS5 Protein Expressed inEscherichia coliExhibits RNA-Dependent RNA Polymerase Activity | |
| Falgout et al. | Proper processing of dengue virus nonstructural glycoprotein NS1 requires the N-terminal hydrophobic signal sequence and the downstream nonstructural protein NS2a | |
| Echeverri et al. | Amino terminal regions of poliovirus 2C protein mediate membrane binding | |
| Rethwilm et al. | The transcriptional transactivator of human foamy virus maps to the bel 1 genomic region. | |
| Markowitz et al. | Binding of cellular proteins to the regulatory region of BK virus DNA | |
| Baric et al. | Characterization of leader-related small RNAs in coronavirus-infected cells: further evidence for leader-primed mechanism of transcription | |
| Twu et al. | Transcriptional trans-activating function of hepatitis B virus | |
| Bruyere et al. | Effects of mutations in the beet western yellows virus readthrough protein on its expression and packaging and on virus accumulation, symptoms, and aphid transmission | |
| Lin et al. | Characterization of hepatitis delta antigen: specific binding to hepatitis delta virus RNA | |
| Shieh et al. | Identification of a new transcriptional initiation site and the corresponding functional gene 2b in the murine coronavirus RNA genome | |
| Veidt et al. | Synthesis of full-length transcripts of beet western yellows virus RNA: messenger properties and biological activity in protoplasts | |
| US6210675B1 (en) | PT-NANB hepatitis polypeptides | |
| KR100386738B1 (ko) | 씨피45 에이치피아이브이-3 균주를 기재로 하는 생균 약독백신 및 상기 백신 내의 약독화를 확인하는 방법 | |
| Roossinck et al. | Rapid induction and severity of symptoms in zucchini squash (Cucurbita pepo) map to RNA 1 of cucumber mosaic virus | |
| Furuya et al. | Three different cellular proteins bind to complementary sites on the 5'-end-positive and 3'-end-negative strands of mouse hepatitis virus RNA | |
| EP0699751A1 (fr) | Antisens complémentaire ou génome d'HCV | |
| Liu et al. | A 100-kilodalton polypeptide encoded by open reading frame (ORF) 1b of the coronavirus infectious bronchitis virus is processed by ORF 1a products | |
| Colinas et al. | A DNA ligase gene in the Copenhagen strain of vaccinia virus is nonessential for viral replication and recombination | |
| CA2197569A1 (fr) | Sequences de nucleotides et d'aminoacides des genes de l'enveloppe (1) et du noyau du virus de l'hepatite | |
| Martin et al. | Identification and analysis of three myristylated vaccinia virus late proteins | |
| Pogue et al. | 5'sequences of rubella virus RNA stimulate translation of chimeric RNAs and specifically interact with two host-encoded proteins | |
| Liu et al. | Proteolytic mapping of the coronavirus infectious bronchitis virus 1b polyprotein: evidence for the presence of four cleavage sites of the 3C-like proteinase and identification of two novel cleavage products | |
| WO1990012101A1 (fr) | Vecteurs de la vaccine, genes de la vaccine et leurs produits d'expression | |
| CA2070952A1 (fr) | Gene du virus de l'hepatite c ou fragment dudit gene, polypeptide code par le gene | |
| EP1878797B1 (fr) | Peptides antigéniques pour le groupage du virus de l'hépatite C, kit comprenant ceux-ci et procédé de groupage les utilisant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |